30652-12-1

Usage

Uses

Different sources of media describe the Uses of 30652-12-1 differently. You can refer to the following data:
1. 1-Ethyl-3-hydroxy-2-methyl-4(1H)-pyridinone is used as iron chelating agent, it is used for the local treatment of skin microcirculatory disorders.
2. It is used as iron chelating agent. Hydroxypyridinones are used for the local treatment of skin microcirculatory disorders.

InChI:InChI=1/C8H11NO2/c1-3-9-5-4-7(10)8(11)6(9)2/h4-5,11H,3H2,1-2H3

Upstream product

• 118-71-8 Maltol 
• 75-04-7 ethylamine 
• 3420-59-5 isomaltol 
• 82756-28-3 3-(β-D-galactopyranosyloxy)-2-furanyl methyl ketone 
• 61049-69-2 3-O-benzylmaltol 

Relevant academic research and scientific papers

Efficient syntheses of N-alkyl-3-hydroxy-2-methyl-4(1H)-pyridinones from carbohydrate precursors

N-alkyl-3-hydroxy-2-methyl-4(1H)-pyridinones can be synthesised in reasonable yield from either 1-(3-hydroxy-2-furanyl)ethanone or O- galactosylisomaltol. Since these carbohydrate precursors can be produced from the disaccharide, α-D-lactose, a simple and inexpensive transformation into pyridinones is possible.

Synthesis and in vitro trypanocidal activity of some novel iron chelating agents

This report describes the syntheses and in vitro trypanocidal activity of a number of iron(III) chelators against epimastigotes of Trypanosoma cruzi. The compounds examined included a number of lipophilic N-alkyl derivatives of 2-ethyl- and 2-methyl-3-hydroxypyrid-4-ones, N,N'-bis(o-hydroxybenzyl)-(±)-trans-1,2-diaminocyclohexane, cyclotetrachromotropylene and four commercially available carboxy derivatives of pyridine, pyrazine, and pyarazole. Benznidazole, the drug clinically used in the treatment of Chagas' disease in humans, served as standard. All compounds were screened in vitro against Trypanosoma cruzi epimastigotes at 50 and 100 μg/ml for 72 h of exposure. At 100 μg/ml dosage, at least 4 compounds exhibited high epimastigote growth inhibition (65-69%) comparable to benznidazole (72%), whereas 9 compounds showed moderate to fair activity (53-64%) in the in vitro assay. At the lower concentration (50 μg/ml), the inhibitory activity of the best of these compounds was reduced significantly (39-48%) compared to the standard drug (59%). The activity of all the carboxylic acids remained in the lower range (4-25%). It is hypothesized that the enhanced activity of some of the compounds is due to their increased lipophilicity which enables them to successfully pass through the cellular membrane of Trypanosoma cruzi epimastigotes. The trypanocidal activities of the most effective compounds were significantly reduced when tested in the presence of added ferric ion.

Technetium-99m complexes with N-substituted 3-hydroxy-4-pyridinones

Disclosed are cationic complexes of Tc-99m and ligands having the structure: STR1 wherein: R1 is hydrogen or is selected from the group consisting of C1 to C20 alkyl; C3 to C12 cycloalkyl; C7/su

Stabilization of organic compounds

Admixture of insulin and a hydroxypyridone being: (1) a 3-hydroxypyrid-4-one in which the hydrogen atom attached to the nitrogen atom is replaced by an aliphatic acyl group, by an aliphatic hydrocarbon group, or by an aliphatic hydrocarbon group substituted by one or more substituents selected from aliphatic acyl, alkoxy, cycloalkoxy, aliphatic amide, aliphatic ester, halogen and hydroxy groups and, optionally, in which one or more of the hydrogen atoms attached to ring carbon atoms are replaced by an aliphatic acyl, alkoxy, cycloalkoxy, aliphatic amide, aliphatic ester, halogen or hydroxy group, by an aliphatic hydrocarbon group, or by an aliphatic hydrocarbon group substituted by an alkoxy, cycloalkoxy, aliphatic ester, halogen or hydroxy group, or a salt thereof.

Process for producing pyrid-4-ones

Substituted-3-hydroxy-pyrid-4-ones, derivatives thereof, and salts thereof are produced by reacting subsituted-3-hydroxypyr-4-one with ammonia or a non-sterically hindered primary amine usually in the presence of a solvent such as water. Also disclosed are novel derivatives of 2-ethyl-3-hydroxypyrid-4-one.

New synthetic approach and iron chelating studies of 1-alkyl-2-methyl-3-hydroxypyrid-4-ones

The major diseases of iron metabolism are iron deficiency anaemia, which could be treated using Fe2+ or Fe3+ salt supplements, and iron overload, which could arise either from an increased gastrointestinal absorption of iron or from recurrent blood transfusions. While the former form of iron overload could be treated by phlebotomy the latter requires the use of a chelator. Desferrioxamine is the only clinically available chelator for the treatment of iron overload but its use worldwide is limited because it is expensive and orally inactive. Several α-ketohydroxy heteroaromatic chelators have been synthesised and tested for their iron binding properties at physiological pH. The synthetic route involves the benzylation of the hydroxyl group of maltol using benzyl chloride, the conversion of the benzylated maltol to the 1-alkyl benzylated pyridine derivative by introducing the corresponding alkylamine in alkaline conditions and the cleavage of the benzyl group in acid to form the 1-alkyl-2-methyl-3-hydroxypyrid-4-one. All the chelators are water soluble and stable at a wide range of pH, forming stable, water soluble, coloured iron complexes with a molar ratio of approximately 3 chelator:1 iron at pH 7.4 and lower molar ratio of chelators to iron complexes at acidic pH. When the 1-methyl, 1-ethyl and 1-propyl, -2-methyl-3-hydroxypyrid-4-ones were mixed at pH 7.4 with transferrin, ferritin and haemosiderin substantial amounts of iron were released. The low cost of synthesis, the strong iron binding properties of these chelators and their other in vitro and in vivo iron mobilising effects increase the prospects of their use in many aspects of iron metabolism and the possible treatment of related diseases particularly iron overload.

Iron complexes of hydroxy pyridones useful for treating iron deficiency anemia

Pharmaceutical compositions containing an iron complex of a 3-hydroxypyrid-2-one or 3-hydroxypyrid-4-one in which the hydrogen atom attached to the nitrogen atom is replaced by an aliphatic hydrocarbon group and, optionally, in which one or more of the hydrogen atoms attached to ring carbon atoms are also replaced by an aliphatic hydrocarbon group, are of value for the treatment of iron deficiency anemia.